Yondelis FDA Approval History
FDA Approved: Yes (First approved October 23, 2015)
Brand name: Yondelis
Generic name: trabectedin
Dosage form: for Injection
Company: Janssen Biotech, Inc.
Treatment for: Soft Tissue Sarcoma
Yondelis (trabectedin) is a cytotoxic antitumor agent for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma, two common subtypes of soft tissue sarcoma.
Development timeline for Yondelis
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
